“AFTER ALMOST 2 YEARS OF FOCUSED RESEARCH, I AM A BELIEVER”, DR MATT DUN, HUNTER MEDICAL RESEARCH INSTITUTE (HMRI), UNIVERSITY OF NEWCASTLE
At ANTG we partner with leading scientists, medical institutions and research centres to improve medical knowledge and efficacy. We’re expanding our understanding of additional uses for medicinal cannabis in preventing and treating diseases and improving people’s lives. In conjunction with the HMRI and lead biomedical scientist Dr Matt Dun, we’re investigating the anticancer properties of our plant varieties. Dr Matt Dun shares his initial thoughts on the joint research project:
“Firstly, thank you for entrusting our research team to investigate the anticancer properties of your plant varieties. When we first met, I had never considered the potential of medicinal cannabis for the treatment of cancer. This was probably due to the lack of published, high-impacting research and / or the controversy shrouding the field. After almost 2 years of focused research, I am a believer. Our data shows that ANTG’s EVE plant extracts kill cancer cells. We are investigating how this happens and hope to provide patients diagnosed with notoriously hard to treat cancers with treatment options.” – @Dr Matt Dun
We’re thrilled to announce we have received our export licence from the Drug Control Section of the ODC (Office of Drug Control). We’re firmly on course to continue to lead the way and be the first medicinal cannabis company in Australia to export cannabis flower to the EU since export was legalised in 2018.
One of ANTG’s proprietary medicinal cannabis strains, EVE Cannabis Indica, has been listed on the Australian Register of Therapeutic Goods (ARTG). The ARTG is a reference of therapeutic goods that can lawfully be supplied in or exported from Australia.
We are focused on research and development, partnering with leading scientists and medical institutions to develop cannabinoid medicines that offer safe and effective therapeutic benefits.LEARN ABOUT ANTG HERE >